Arbutamine stress echocardiography

European Heart Journal
T KettelerH Gülker

Abstract

Arbutamine, a new potent non-selective beta-adrenoceptor agonist with mild alpha 1-sympathomimetic activity, has been developed specifically for pharmacological stress testing. The drug acts like physical exercise, increasing both heart rate and myocardial contractility. Sensitivity, specificity and accuracy in detecting significant stenotic coronary artery disease are 76%, 96%, and 82%, respectively, again similar to those of exercise echocardiography. The drug is delivered by a computerized drug delivery and monitoring device (GenESA) which adjusts the infusion rate according to the patient's heart rate data feedback. The drug is generally well tolerated and has an acceptable safety profile. This article describes recent clinical experience with arbutamine and presents preliminary results of a multicentre multinational study which evaluates the clinical utility and safety of the GenESA system in diagnosing coronary artery disease.

Citations

Dec 20, 2003·Progress in Cardiovascular Diseases·Rita F Redberg, Leslee J Shaw
Dec 18, 2001·International Journal of Cardiology·J Ali RazaA Movahed
Feb 15, 2001·Echocardiography·Steven C. Smart, Kiran B. Sagar
Sep 9, 2000·Echocardiography·S C Smart, K B Sagar
Feb 15, 2001·Echocardiography·Cherian SebastianKrishnaswamy Chandrasekaran
Jun 26, 2004·Postgraduate Medicine·Tahir Tak, Ricardo Gutierrez
Feb 21, 2006·The Journal of Cardiovascular Nursing·Kristine A Scordo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.